GlassScriptPhysician profile
Jagdish Lal
NPI 1083802763
$2,607.84
in general payments reported to CMS, 2019-2025
32 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $81.93 · 2021: $297 · 2022: $326 · 2023: $313 · 2024: $419 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $332.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $324.09 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $274.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $224.96 | 2021-2025 | |
| Lilly USA, LLC | $200.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Akcea Therapeutics, INC. | $185.05 | 2019 | |
| Shield Therapeutics INC | $121.37 | 2024-2025 | |
| Abbott Laboratories | $113.59 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $85.95 | 2022-2024 | |
| Baxter Healthcare | $84.47 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amneal Pharmaceuticals LLC | $70.39 | 2023 | Lyvispah |
| Amgen INC. | $63.93 | 2024-2025 | Otezla, Repatha, Otezla |
| Neotract INC. | $55.90 | 2019 | |
| Aytu Biopharma, INC. | $46.41 | 2019 | |
| Eisai INC. | $43.41 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $43.25 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vifor Pharma, INC. | $39.49 | 2020-2023 | Veltassa |
| Horizon Therapeutics Plc | $34.07 | 2021-2022 | |
| Astellas Pharma US INC | $29.79 | 2019 | |
| Amarin Pharma, INC. | $27.51 | 2020-2021 | |
| Pfizer INC. | $26.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $18.47 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.42 | 2022 | |
| Daiichi Sankyo INC. | $16.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.75 | 2019 | |
| Genentech USA, INC. | $14.94 | 2019 | |
| Edwards Lifesciences Corporation | $14.42 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $13.30 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagdish Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.